纽阿姆斯特丹制药披露纳斯达克上市规则5635(c)(4)项下的激励性授予

投资观察09-04

9月3日（路透社）——纽阿姆斯特丹制药公司（NewAmsterdam Pharma Company N.V.）于今日正式对外宣布，公司已依据纳斯达克上市规则第5635(c)(4)条款，完成了一系列激励性股票授予的相关报告事宜。

此项公告标志着公司在其股权激励计划框架下，进一步落实了对关键人才的吸引与留任策略。通过此类授予，公司旨在将管理层及核心员工的利益与股东价值创造更紧密地绑定在一起。

上述授予行为严格遵循了纳斯达克关于此类激励性补偿的特定披露要求，体现了公司在公司治理与合规运营方面的承诺。

（本报道基于路透社投资者简报整理）

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohunote.com/m/news/1115930814?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-09-04 05:47","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1115930814","market":"us","top_or_hot":-1,"title":"纽阿姆斯特丹制药披露纳斯达克上市规则5635(c)(4)项下的激励性授予","media":"投资观察","content":"<p>9月3日（路透社）——纽阿姆斯特丹制药公司（NewAmsterdam Pharma Company N.V.）于今日正式对外宣布，公司已依据纳斯达克上市规则第5635(c)(4)条款，完成了一系列激励性股票授予的相关报告事宜。</p>\n<p>此项公告标志着公司在其股权激励计划框架下，进一步落实了对关键人才的吸引与留任策略。通过此类授予，公司旨在将管理层及核心员工的利益与股东价值创造更紧密地绑定在一起。</p>\n<p>上述授予行为严格遵循了纳斯达克关于此类激励性补偿的特定披露要求，体现了公司在公司治理与合规运营方面的承诺。</p>\n<p>（本报道基于路透社投资者简报整理）</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>纽阿姆斯特丹制药披露纳斯达克上市规则5635(c)(4)项下的激励性授予</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n纽阿姆斯特丹制药披露纳斯达克上市规则5635(c)(4)项下的激励性授予\n</h2>\n\n<h4 class=\"meta\">\n\n2026-09-04 05:47 北京时间&nbsp;&nbsp;&nbsp;<strong>投资观察</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>9月3日（路透社）——纽阿姆斯特丹制药公司（NewAmsterdam Pharma Company N.V.）于今日正式对外宣布，公司已依据纳斯达克上市规则第5635(c)(4)条款，完成了一系列激励性股票授予的相关报告事宜。\n此项公告标志着公司在其股权激励计划框架下，进一步落实了对关键人才的吸引与留任策略。通过此类授予，公司旨在将管理层及核心员工的利益与股东价值创造更紧密地绑定在一起。\n上述授予...</p>\n\n<a href=\"\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"","article_id":"1115930814","we_media_id":"1076224072","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1115930814","pubTimestamp":1788472069,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"投资观察","introduction":"关注海外资本市场一手动态","home_visible":1,"id":"1076224072","head_image":"https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922"},"summary":"9月3日（路透社）——纽阿姆斯特丹制药公司（NewAmsterdam Pharma Company N.V.）于今日正式对外宣布，公司已依据纳斯达克上市规则第5635(c)(4)条款，完成了一系列激励性股票授予的相关报告事宜。\n此项公告标志着公司在其股权激励计划框架下，进一步落实了对关键人才的吸引与留任策略。通过此类授予，公司旨在将管理层及核心员工的利益与股东价值创造更紧密地绑定在一起。\n上述授予行为严格遵循了纳斯达克关于此类激励性补偿的特定披露要求，体现了公司在公司治理与合规运营方面的承诺。\n（本报道基于路透社投资者简报整理）","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4139":"生物科技","NAMS":"NEWAMSTERDAM PHARMA CO NV"},"translate_title":"New Amsterdam Pharmaceuticals discloses incentive grants under Nasdaq Listing Rules 5635(c)(4)","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NAMS":1},"content_text":"9月3日（路透社）——纽阿姆斯特丹制药公司（NewAmsterdam Pharma Company N.V.）于今日正式对外宣布，公司已依据纳斯达克上市规则第5635(c)(4)条款，完成了一系列激励性股票授予的相关报告事宜。\n此项公告标志着公司在其股权激励计划框架下，进一步落实了对关键人才的吸引与留任策略。通过此类授予，公司旨在将管理层及核心员工的利益与股东价值创造更紧密地绑定在一起。\n上述授予行为严格遵循了纳斯达克关于此类激励性补偿的特定披露要求，体现了公司在公司治理与合规运营方面的承诺。\n（本报道基于路透社投资者简报整理）","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"executive","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1115930814","isCrawlerRequest":true}